Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study)

Mayke B G Koek, Erik Buskens, Huib van Weelden, Paul H A Steegmans, Carla A F M Bruijnzeel-Koomen, Vigfús Sigurdsson, Mayke B G Koek, Erik Buskens, Huib van Weelden, Paul H A Steegmans, Carla A F M Bruijnzeel-Koomen, Vigfús Sigurdsson

Abstract

Objective: To determine whether ultraviolet B phototherapy at home is equally safe and equally effective as ultraviolet B phototherapy in an outpatient setting for patients with psoriasis.

Design: Pragmatic multicentre single blind randomised clinical trial (PLUTO study).

Setting: Dermatology departments of 14 hospitals in the Netherlands.

Participants: 196 patients with psoriasis who were clinically eligible for narrowband (TL-01) ultraviolet B phototherapy. The first 105 consecutive patients were also followed for one year after therapy.

Intervention: Ultraviolet B phototherapy at home using a TL-01 home phototherapy unit compared with standard narrowband ultraviolet B phototherapy in an outpatient setting. Both therapies were done in a setting reflecting routine daily practice in the Netherlands.

Main outcome measures: The main outcome measure was effectiveness as measured by the proportion of patients with a 50% or more reduction of the baseline psoriasis area and severity index (PASI) or self administered psoriasis area and severity index (SAPASI), called the PASI 50 and SAPASI 50 (relevant treatment effect). Another outcome of effectiveness was the percentage reduction in median scores on the PASI as well as SAPASI. Also the proportions of patients reaching the PASI 75 and SAPASI 75 (successful treatment effect), and the PASI 90 and SAPASI 90 (almost complete clearance) were calculated. Other secondary outcomes were quality of life (SF-36, psoriasis disability index), burden of treatment (questionnaire), patients' preferences and satisfaction (questionnaire), and dosimetry and short term side effects (diary).

Results: 82% of the patients treated at home compared with 79% of the patients treated in an outpatient setting reached the SAPASI 50 (difference 2.8%, 95% confidence interval -8.6% to 14.2%), and 70% compared with 73% reached the PASI 50 (-2.3%, -15.7% to 11.1%). For patients treated at home the median SAPASI score decreased 82% (from 6.7 to 1.2) and the median PASI score decreased 74% (from 8.4 to 2.2), compared with 79% (from 7.0 to 1.4) and 70% (from 7.0 to 2.1) for patients treated in an outpatient setting. Treatment effect as defined by the mean decline in PASI and SAPASI scores was significant (P<0.001) and similar across groups (P>0.3). Total cumulative doses of ultraviolet B light were similar (51.5 v 46.1 J/cm(2), difference 5.4, 95% confidence interval -5.2 to 16.0), and the occurrence of short term side effects did not differ. The burden of undergoing ultraviolet B phototherapy was significantly lower for patients treated at home (differences 1.23 to 3.01, all P</=0.001). Quality of life increased equally regardless of treatment, but patients treated at home more often rated their experience with the therapy as "excellent" (42%, 38/90) compared with patients treated in the outpatient department (23%, 20/88; P=0.001).

Conclusion: Ultraviolet B phototherapy administered at home is equally safe and equally effective, both clinically and for quality of life, as ultraviolet B phototherapy administered in an outpatient setting. Furthermore, ultraviolet B phototherapy at home resulted in a lower burden of treatment and led to greater patients' satisfaction. Trial registration Current Controlled Trials ISRCTN83025173 and Clinicaltrials.gov NCT00150930.

Conflict of interest statement

Competing interests: None declared.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787591/bin/koem564773.f1_default.jpg
Fig 1 Schematic representation of planned measurements. PASI=psoriasis area and severity index; SAPASI=self administered psoriasis area and severity index
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787591/bin/koem564773.f2_default.jpg
Fig 2 Flow of patients through trial
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787591/bin/koem564773.f3_default.jpg
Fig 3 Median self administered psoriasis area and severity index (SAPASI) scores against time. 0=baseline (98 home patients v 98 outpatients); 1=start of therapy (93 v 94), 2=23 irradiations (90 v 74), 3=end of therapy (when ultraviolet B treatment exceeded 46 irradiations, the 46th irradiation was defined as end of therapy; 94 v 91), 4=2 months after therapy (51 v 43), 5=4 months after therapy (52 v 44), 6=6 months after therapy (50 v 44), 7=8 months after therapy (50 v 43), 8=10 months after therapy (49 v 42), 9=12 months after therapy (47 v 40). From measurement 0-3 all 196 participants were followed. From measurement 4-9 only a consecutive sample of 105 participants was followed
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787591/bin/koem564773.f4_default.jpg
Fig 4 Mean burden of treatment values on a 0-10 visual analogue scale for 92 patients randomised to receive ultraviolet B phototherapy at home and 89 to receive ultraviolet B phototherapy in an outpatient setting. Error bars are 95% confidence intervals. *For example, location of treatment (home v hospital), positioning for irradiation, actions for patient to perform. †Includes use of creams and ointments or taking drugs for psoriasis (87 home patients v 83 outpatients)
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787591/bin/koem564773.f5_default.jpg
Fig 5 Patients’ self rated global experience of ultraviolet B phototherapy

References

    1. Anon. An appraisal of narrowband (TL-01) UVB phototherapy. British Photodermatology Group workshop report (Apr 1996). Br J Dermatol 1997;137:327-30.
    1. Ibbotson SH, Bilsland D, Cox NH, Dawe RS, Diffey B, Edwards C, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group workshop report. Br J Dermatol 2004;151:283-97.
    1. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005;152:597-615.
    1. Barbagallo J, Spann CT, Tutrone WD, Weinberg JM. Narrowband UVB phototherapy for the treatment of psoriasis: a review and update. Cutis 2001;68:345-7.
    1. Milstein HJ, Vonderheid EC, Van Scott EJ, Johnson WC. Home ultraviolet phototherapy of early mycosis fungoides: preliminary observations. J Am Acad Dermatol 1982;6:355-62.
    1. Resnik KS, Vonderheid EC. Home UV phototherapy of early mycosis fungoides: long-term follow-up observations in thirty-one patients. J Am Acad Dermatol 1993;29:73-7.
    1. Larko O, Swanbeck G. Home solarium treatment of psoriasis. Br J Dermatol 1979;101:13-6.
    1. Jordan WP Jr, Clarke AM, Hale RK. Long-term modified Goeckerman regimen for psoriasis using an ultraviolet B light source in the home. J Am Acad Dermatol 1981;4:584-91.
    1. Van Vloten WA. [Home treatment of psoriasis using ultraviolet-B irradiation]. Ned Tijdschr Geneeskd 1993;137:2525-6.
    1. Matto DM, van den Berg-Tap RMC. [Phototherapy at home. More privacy for patients with psoriasis]. Medisch Contact 2003;58(23):950-2.
    1. Cameron H, Yule S, Moseley H, Dawe RS, Ferguson J. Taking treatment to the patient: development of a home TL-01 ultraviolet B phototherapy service. Br J Dermatol 2002;147:957-65.
    1. Lowe NJ. Home ultraviolet phototherapy. Semin Dermatol 1992;11:284-6.
    1. Feldman SR, Clark A, Reboussin DM, Fleischer AB Jr. An assessment of potential problems of home phototherapy treatment of psoriasis. Cutis 1996;58:71-3.
    1. Physicians change attitude about home UVB treatment. Natl Psoriasis Found Bull 1991;22:15.
    1. Gerritsen MJP. [Home treatment of psoriasis using ultraviolet B irradiation]. Ned Tijdschr Dermatol Venereol 2000;10:101-2.
    1. Sarkany RPE, Anstey A, Diffey BL, Jobling R, Langmack K, McGregor JM, et al. Home phototherapy: report on a workshop of the British Photodermatology Group, December 1996. Br J Dermatol 1999;140:195-9.
    1. Prince A, van Leussen J. [Home treatment of psoriasis using ultraviolet B irradiation]. Ned Tijdschr Geneeskd 1994;138:373-4.
    1. Abel EA. Considerations in the use of home ultraviolet radiation therapy for psoriasis. Cutis 1985;35:127-8, 130.
    1. Paul BS, Stern RS, Parrish JA, Arndt KA. Low-intensity selective UV phototherapy. A clinical trial in outpatient therapy for psoriasis. Arch Dermatol 1983;119:122-4.
    1. Task Force on Psoriasis of the Netherlands Society for Dermatology and Venereology. [Guideline: Photo(chemo)therapy and systemic therapy in severe chronic plaque type psoriasis]. 2008. ?
    1. Murphy GM, McCann P, O’Leary A, Rogers S. Guidelines for the use of phototherapy and photochemotherapy in Ireland. Ir J Med Sci 1997;166:92-7.
    1. Committee on Guidelines of Care, Task Force on Phototherapy and Photochemotherapy. Guidelines of care for phototherapy and photochemotherapy. J Am Acad Dermatol 1994;31:643-8.
    1. Committee on Guidelines of Care, Task Force on Psoriasis. Guidelines of care for psoriasis. J Am Acad Dermatol 1993;28:632-7.
    1. Biella U, Heller G, Barth J, Borissenko KK, Korotkij NG, Horkay I, et al. [Survey on current status of home treatment of psoriasis patients with ultraviolet irradiation equipment]. Z Arztl Fortbild (Jena) 1985;79(12):531-3.
    1. Koek MBG, Buskens E, Bruijnzeel-Koomen CAFM, Sigurdsson V. Home ultraviolet B phototherapy for psoriasis: discrepancy between literature, guidelines, general opinions and actual use. Results of a literature review, a web search, and a questionnaire among dermatologists. Br J Dermatol 2006;154:701-11.
    1. Koek MBG, Buskens E, Steegmans PHA, van Weelden H, Bruijnzeel-Koomen CAFM, Sigurdsson V. UVB phototherapy in an outpatient setting or at home: a pragmatic randomised single-blind trial designed to settle the discussion. The PLUTO study. BMC Med Res Methodol 2006;6:39.
    1. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chron Dis 1967;20:637-48.
    1. Roland M, Torgerson DJ. What are pragmatic trials? BMJ 1998;316:285.
    1. Pragmatic versus explanatory trials. 2008. .
    1. Soares I, Carneiro AV. Intention-to-treat analysis in clinical trials: principles and practical importance. Rev Port Cardiol 2002;21:1191-8.
    1. Pocock SJ. The size of a clinical trial. Clinical trials. A practical approach. Chichester: Wiley, 1993:123-41.
    1. Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997;137:943-9.
    1. Pocock SJ. Methods of randomization. Clinical trials. A practical approach. Chichester: Wiley, 1993:66-89.
    1. Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
    1. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Exum ML, Clark AR, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996;106:183-6.
    1. Fleischer AB Jr, Rapp SR, Reboussin DM, Vanarthos JC, Feldman SR. Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol 1994;102:967-9.
    1. Fleischer AB Jr, Feldman SR, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol 1999;26:210-5.
    1. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I: conceptual framework and item selection. Med Care 1992;30:473-83.
    1. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol 1998;51:1055-68.
    1. Finlay AY, Kelly SE. Psoriasis—an index of disability. Clin Exp Dermatol 1987;12:8-11.
    1. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol 1990;123:751-6.
    1. Trochim WMK. Regression to the mean. In: The research methods knowledge base, 2nd edn. 2006. .
    1. De Gruijl FR, van Kranen HJ, Mullenders LH. UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J Photochem Photobiol B 2001;63(1-3):19-27.
    1. Kricker A, Armstrong BK, English DR, Heenan PJ. Does intermittent sun exposure cause basal cell carcinoma? A case-control study in Western Australia. Int J Cancer 1995;60:489-94.
    1. Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst 1984;73:75-82.
    1. Parrish JA, Jaenicke KF, Anderson RR. Erythema and melanogenesis action spectra of normal human skin. Photochem Photobiol 1982;36:187-91.
    1. Van Weelden H, De La Faille HB, Young E, van der Leun JC. A new development in UVB phototherapy of psoriasis. Br J Dermatol 1988;119:11-9.
    1. Snellman E, Jansen CT, Leszczynski K, Visuri R, Milan T, Jokela K. Ultraviolet erythema sensitivity in anamnestic (I-IV) and phototested (1-4) Caucasian skin phototypes: the need for a new classification system. Photochem Photobiol 1995;62:769-72.
    1. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988;124:869-71.
    1. Slaper H, Schothorst AA, van der Leun JC. Risk evaluation of UVB therapy for psoriasis: comparison of calculated risk for UVB therapy and observed risk in PUVA-treated patients. Photodermatol 1986;3:271-83.
    1. Yelverton CB, Yentzer BA, Clark A, Pearce DJ, Balkrishnan R, Camacho FT, et al. Home narrowband UV-B phototherapy in combination with low-dose acitretin in patients with moderate to severe psoriasis. Arch Dermatol 2008;144:1224-5.
    1. Cameron H, Dawe RS, Yule S, Murphy J, Ibbotson SH, Ferguson J. A randomized, observer-blinded trial of twice vs three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol 2002;147:973-8.
    1. Dawe RS, Wainwright NJ, Cameron H, Ferguson J. Narrow-band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? Br J Dermatol 1998;138:833-9.
    1. Kirke SM, Lowder S, Lloyd JJ, Diffey BL, Matthews JN, Farr PM. A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. J Invest Dermatol 2007;127:1641-6.
    1. Gupta G, Long J, Tillman DM. The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures. Br J Dermatol 1999;140:887-90.
    1. Tanew A, Radakovic-Fijan S, Schemper M, Honigsmann H. Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study. Arch Dermatol 1999;135:519-24.
    1. Leaute-Labreze C, Saillour F, Chene G, Cazenave C, Luxey-Bellocq ML, Sanciaume C, et al. Saline spa water or combined water and UV-B for psoriasis vs conventional UV-B: lessons from the Salies de Bearn randomized study. Arch Dermatol 2001;137:1035-9.
    1. Carrozza P, Hausermann P, Nestle FO, Burg G, Boni R. Clinical efficacy of narrow-band UVB (311 nm) combined with dithranol in psoriasis. An open pilot study. Dermatology 2000;200:35-9.
    1. Heydendael VMR, Spuls PI, Opmeer BC, de Borgie CAJM, Reitsma JB, Goldschmidt WFM, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65.
    1. Flytstrom I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008;158:116-21.
    1. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
    1. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
    1. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42.
    1. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2007;158:558-66.
    1. Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007;57:269-75.
    1. German Dermatological Society (DDG) Professional Association of German Dermatologists (BVDD), German Psoriasis Foundation (DPB). [Consensus letter home UV treatment for psoriasis]. 18 Feb, 1999.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться